Caplin Point Laboratories Limited (CAPLIPOINT)
Valuation Rating
Score: 17/100
Valuation Overview
| P/E Ratio | 33.736443 |
| P/B Ratio | 6.701415 |
| Dividend Yield | 0.22999999999999998% |
| Current Price | ₹2177.35 |
| DCF Value | ₹342.5905796090802 |
| Upside Potential | N/A% |
Intrinsic Values
| Current Price | ₹2177.35 |
| DCF Value | ₹342.5905796090802 |
| Graham Value | ₹806.7500000000001 |
| DDM Value | ₹72.14285714285714 |
| Earnings Value | ₹1319.87324115642 |
| Average Value | ₹579.2635681454601 |
Growth Confidence
| Revenue Growth | 0% |
| Earnings Growth | 0% |
| Revenue Confidence | 0% |
| Earnings Confidence | 0% |
| Margin Confidence | 0% |
| Overall Growth Confidence | 0% |
Growth Metrics
| EPS Growth | 13.7% |
| Revenue Growth | 17.8% |
| Market Cap | ₹16550.41 Cr |
Valuation Analysis Score: 17/100
Undervaluation Score: 17/100
Valuation Score: 10/30
Growth Score: 7/30
Intrinsic Value Score: 0/40
Growth Score: 7/30
Intrinsic Value Score: 0/40
Key Analysis Points:
- Excellent operating margins above 20%
- Good growth confidence score above 60%
Recommendation
Caution - Stock may be overvalued, detailed analysis recommended
Detailed Metrics
Current Price: ₹2,177.35
Operating Margins: 30.6%
Revenue Growth: 0.0%
Earnings Growth: 0.0%
Growth Confidence: 62.7%
Risk Assessment Guide
- Score 80-100: Significantly undervalued with strong fundamentals
- Score 60-79: Moderately undervalued with good potential
- Score 40-59: Fairly valued with balanced metrics
- Score Below 40: Potentially overvalued, exercise caution
Last Updated: 2025-01-23 07:01:42